Sign in

    Lucy-Emma Codrington-Bartlett • Jefferies

    Lucy-Emma Codrington-Bartlett's questions to Zealand Pharma A/S (ZLDPF) leadership

    Lucy-Emma Codrington-Bartlett's questions to Zealand Pharma A/S (ZLDPF) leadership • Q3 2024

    Question

    Lucy-Emma Codrington-Bartlett inquired about the design of the petrelintide Phase IIb trial, specifically the dose arms and Phase III intentions. She also asked about potential taste aversion side effects seen in competitor amylin assets and sought clarification on the dasiglucagon filing delay and any potential impact on glepaglutide's approval.

    Answer

    President and CEO Adam Steensberg confirmed that data analysis for the dasiglucagon submission is complete and the company feels comfortable that the third-party manufacturing issue, which he described as a timing problem, will be resolved without impacting glepaglutide. Chief Medical Officer David Kendall clarified the Phase IIb trial uses different maximal doses with similar titration schemes. He also stated that taste aversion has not been observed with petrelintide and is likely linked to CGRP receptor activity, which their molecule lacks, rather than calcitonin activity.

    Ask Fintool Equity Research AI

    Lucy-Emma Codrington-Bartlett's questions to Zealand Pharma A/S (ZLDPF) leadership • Q3 2024

    Question

    Lucy-Emma Codrington-Bartlett inquired about the petrelintide Phase IIb trial design, specifically the dose arms and Phase III intentions. She also asked about potential taste aversion side effects and sought clarification on the dasiglucagon filing timeline and its potential impact on glepaglutide.

    Answer

    CEO Adam Steensberg and Chief Medical Officer David Kendall responded. Dr. Kendall clarified the Phase IIb trial uses five distinct maximal doses with a similar titration scheme, keeping the option for multiple doses in Phase III open. He stated that taste aversion has not been observed with petrelintide and is likely linked to CGRP receptor activity, which their molecule lacks. Mr. Steensberg confirmed the dasiglucagon data analysis is complete, and they are awaiting a regulatory update on the third-party manufacturer, expressing confidence it will not delay glepaglutide.

    Ask Fintool Equity Research AI